
MAIA Biotechnology, Inc.
93
Recent developments highlight MAIA's progress in clinical trial enrollment and geographic expansion, alongside presentations of next-generation drug data and regulatory milestones.
- MAIA completed enrollment in THIO-101 Part C and Phase 3 enrollment reached 65% as of October 7, 2026 [N1].
- The company broadened its Phase 3 lung cancer study footprint across Europe, activating multiple clinical sites [N2].
- MAIA reached an enrollment milestone of 65 patients in the Phase 3 THIO-104 trial for ateganosine in lung cancer [N3].
- Industry commentary noted MAIA among biotech stocks with fresh catalysts in September 2026 [N4].
- MAIA dosed the first U.S. patient in the Phase 2 THIO-101 trial for advanced NSCLC [N5].
- MAIA presented next-generation drug data for ateganosine at the IRT 2026 conference [N6].
- The company reported increased disease control rates from Phase 2 THIO-101 for ateganosine in lung cancer [N7].
- MAIA completed international enrollment in Phase 2 THIO-101 Part C for ateganosine in lung cancer [N8].
MAIA Biotechnology, Inc. operates as a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer treatment. Its lead product candidate, ateganosine, is designed to target telomeres and stimulate immune responses against cancer cells, particularly in advanced NSCLC patients who have progressed beyond standard therapies. The company conducts clinical trials globally, including Phase 2 and Phase 3 studies, often in combination with immune checkpoint inhibitors such as Regeneron's cemiplimab and BeOne Medicines' tislelizumab. MAIA has received FDA fast track designation for ateganosine and is pursuing regulatory pathways for accelerated approval. Financially, the company is pre-revenue and reports ongoing net losses consistent with clinical-stage biopharmaceutical firms.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing ateganosine, a telomere-targeting immunotherapy for advanced non-small cell lung cancer (NSCLC) and other cancers. The company has advanced clinical trials including Phase 2 and Phase 3 studies, with regulatory approvals and collaborations supporting its development programs. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, MAIA reported no revenue, a net loss of approximately $7.18 million, and a current ratio of 3.41, reflecting liquidity coverage of short-term liabilities.
MAIA's lead candidate ateganosine has shown encouraging clinical efficacy in Phase 2 trials, including high disease control rates and overall response rates in advanced NSCLC patients resistant to existing therapies. The initiation and progress of a pivotal Phase 3 trial with substantial enrollment and geographic expansion across Europe indicate active clinical development. FDA fast track designation and collaborations with established pharmaceutical companies support regulatory and development pathways. Continued clinical data releases and enrollment milestones may enhance the company's clinical and regulatory visibility.
MAIA remains a clinical-stage company with no approved products or revenue, relying on successful clinical trial outcomes and regulatory approvals for future commercialization. The company reported a net loss and zero cash and equivalents as of September 30, 2026, which may pose liquidity risks. Clinical trials in oncology carry inherent risks including potential failure to demonstrate efficacy or safety. Regulatory pathways such as accelerated approval are not guaranteed. The competitive immuno-oncology landscape and dependency on partnerships add execution risks.
MAIA Biotechnology's moat is based on its proprietary telomere-targeting technology platform and its lead drug candidate ateganosine, which combines telomere disruption with immunogenic effects. The company has established clinical supply agreements with major pharmaceutical partners like Regeneron and collaborations with BeOne Medicines, enhancing its development capabilities. Its clinical trials have demonstrated promising efficacy signals in difficult-to-treat NSCLC populations, supported by FDA fast track designation. The specialized nature of its drug candidate and clinical data may provide competitive differentiation in the immuno-oncology space.
• Clinical Trial Risk: The success of MAIA's business depends on positive outcomes from ongoing and future clinical trials of ateganosine. Failure to demonstrate safety and efficacy could materially impact the company.
• Regulatory Risk: Regulatory approvals including accelerated or fast track designations do not guarantee marketing approval. Delays or denials by the FDA or other authorities could affect development timelines.
• Financial and Liquidity Risk: As of September 30, 2026, MAIA reported zero cash and equivalents and ongoing net losses, which may constrain its ability to fund operations without additional financing.
• Competitive Risk: The immuno-oncology field is highly competitive with multiple companies developing checkpoint inhibitors and telomere-targeting therapies, which may limit market opportunities.
Business trends: Continued clinical trial enrollment progress and geographic expansion in NSCLC and other cancer indications, supported by regulatory fast track designation and collaborations.
Execution milestones: Completion of Phase 2 THIO-101 enrollment, advancement of Phase 3 THIO-104 trial, and presentation of next-generation drug data.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, financial liquidity constraints, and competitive pressures in oncology therapeutics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, primarily focusing on its lead asset, ateganosine (THIO, 6-thio-dG).
- Ateganosine is an investigational drug candidate with a dual mechanism of action involving telomere targeting and immunogenicity, aimed at treating advanced non-small cell lung cancer (NSCLC).
- The company initiated a Phase 2 human trial (THIO-101) in Australia in July 2022 and expanded it to Europe with regulatory approvals in Hungary, Poland, and Bulgaria.
- THIO-101 evaluates ateganosine in combination with Regeneron's immune checkpoint inhibitor Libtayo (cemiplimab) and as monotherapy in third-line NSCLC patients resistant to checkpoint inhibitors and chemotherapy.
- MAIA has a clinical supply agreement with Regeneron for cemiplimab at no cost, granting Regeneron exclusive development rights for combination with PD-1 inhibitors during the study period.
- The company initiated a Phase 3 pivotal trial (THIO-104) in 2025 to evaluate ateganosine in sequence with checkpoint inhibitors in third-line NSCLC patients, targeting up to 300 patients.
- Phase 2 clinical trials for hepatocellular carcinoma (HCC), colorectal cancer (CRC), and small cell lung cancer (SCLC) are planned for 2026 in combination with BeOne Medicines' immune checkpoint inhibitor tislelizumab.
- MAIA received FDA fast track designation for ateganosine in July 2025 and plans to utilize expedited programs for development and review.
- Clinical data from THIO-101 show promising efficacy signals including disease control rates (DCR) up to 100% in second-line treatment and overall response rates (ORR) of 38% in third-line NSCLC patients.
- The company completed enrollment in Phase 2 THIO-101 Part C and Phase 3 enrollment reached 65% as of October 2026.
- MAIA broadened its Phase 3 lung cancer study footprint across Europe and activated multiple clinical sites in the US and Europe.
- Financial snapshot as of September 30, 2026, shows cash and equivalents at $0, current assets of approximately $22.1 million, current liabilities of approximately $6.5 million, and a current ratio of 3.41, indicating liquidity coverage of short-term obligations.
- Net income for the nine months ended September 30, 2026, was a loss of approximately $7.18 million with basic and diluted EPS of -$0.12 per share.
- The company has no reported revenue as of fiscal year 2024.
- MAIA has ongoing collaborations with BeOne Medicines (formerly BeiGene) for clinical trials in multiple cancer indications.
- The company has disclosed no additional risk factors beyond those in its 2025 Annual Report as of the latest quarterly filing.
Generated 2026-11-10
- S1 | 2026-03-23 | 10-K
- S2 | 2026-11-09 | 10-Q
- N1 | 2026-10-07 | www.nasdaq.com | MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65% | https://www.nasdaq.com/articles/maia-completes-thio-101-part-c-enrollment-phase-3-enrollment-hits-65
- N2 | 2026-09-24 | www.nasdaq.com | MAIA Broadens Phase 3 Lung Cancer Study Footprint Across Europe | https://www.nasdaq.com/articles/maia-broadens-phase-3-lung-cancer-study-footprint-across-europe
- N3 | 2026-09-22 | www.nasdaq.com | MAIA Reaches Enrollment Milestone Of 65 In Phase 3 THIO-104 For Ateganosine In Lung Cancer | https://www.nasdaq.com/articles/maia-reaches-enrollment-milestone-65-phase-3-thio-104-ateganosine-lung-cancer
- N4 | 2026-09-16 | www.nasdaq.com | Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA | https://www.nasdaq.com/articles/biotech-stocks-see-fresh-catalysts-tempest-datameds-neuraxis-maia
- N5 | 2026-09-16 | www.nasdaq.com | MAIA Doses First U.S. Patient In Phase 2 THIO-101 Trial For Advanced Non-Small Cell Lung Cancer | https://www.nasdaq.com/articles/maia-doses-first-us-patient-phase-2-thio-101-trial-advanced-non-small-cell-lung-cancer
- N6 | 2026-09-10 | www.nasdaq.com | MAIA Biotechnology Presents Ateganosine, Next-Generation Drug Data At IRT 2026 | https://www.nasdaq.com/articles/maia-biotechnology-presents-ateganosine-next-generation-drug-data-irt-2026
- N7 | 2026-07-08 | www.nasdaq.com | MAIA Reports Increased Disease Control Rate From Phase 2 THIO-101 For Ateganosine In Lung Cancer | https://www.nasdaq.com/articles/maia-reports-increased-disease-control-rate-phase-2-thio-101-ateganosine-lung-cancer
- N8 | 2026-06-26 | www.nasdaq.com | MAIA Completes International Enrollment In Phase 2 THIO-101 Part C For Ateganosine In Lung Cancer | https://www.nasdaq.com/articles/maia-completes-international-enrollment-phase-2-thio-101-part-c-ateganosine-lung-cancer
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


